Emergence of methicillin-resistant Staphylococcus aureus with intermediate glycopeptide resistance: Clinical significance and treatment options

Drugs

Volumn 61, Issue 1, 2001, Pages 1-7

  Rybak, Michael J ^a   Akins, Ronda L ^b  

^a WAYNE STATE UNIVERSITY   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINAFLOXACIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; GENTAMICIN; GLYCOPEPTIDE; LEVOFLOXACIN; LINEZOLID; METICILLIN; PENICILLIN BINDING PROTEIN; RIFAMPICIN; SULTAMICILLIN; TEICOPLANIN; TETRACYCLINE; TROVAFLOXACIN; VANCOMYCIN;

BACTERIAL CELL WALL; DRUG MISUSE; HUMAN; INFECTION CONTROL; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MORBIDITY; MORTALITY; MULTIDRUG RESISTANCE; NONHUMAN; REVIEW; TRANSMISSION ELECTRON MICROSCOPY;

ANTI-BACTERIAL AGENTS; HUMANS; METHICILLIN RESISTANCE; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN;

EID: 0035132479     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200161010-00001     Document Type: Review

References (42)

1. Antimicrobial resistance in key bloodstream bacterial isolates: Electronic surveillance with The Surveillance Network Database - USA
2. Mechanisms of resistance to beta-lactam antibiotics in strains of Staphylococcus aureus
3. Treatment of infections due to methicillin-resistant Staphylococcus aureus
4. The economic impact of Staphylococcus aureus infections in New York City Hospitals
5. Staphylococcus aureus (including toxic shock syndrome)
6. Decreased susceptibilities to teicoplanin and vancomycin among coagulase-negative methicillin-resistant clinical isolates of staphylococci
7. Emergence of vancomycin resistance in coagulase-negative staphylococci
8. Emergence of vancomycin resistance in Staphylococcus aureus
9. Intermediate vancomycin resistance in Staphylococcus aureus: A major threat or a minor inconvenience?
10. The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcusaureus infection
11. New resistance in Staphylococcus aureus
12. Vancomycin-resistant Staphylococcus aureus: Perspectives on measures needed for control
13. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus
14. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin
15. Interim guidelines for prevention and control of staphylococcal infection associated with reduced susceptibility to vancomycin
16. Emergence of heterogeneous intermediate vancomycin resistance in Staphylococcus aureus in the Dusseldorf area
17. Vancomycin resistant Staphylococcus aureus
18. Heterogeneous vancomycin resistance in methicillin-resistant Staphylococcus aureus: Strains isolated in a large Italian Hospital
19. Spread of methicillin-resistant Staphylococcus aureus belonging to the Brazilian epidemic clone in a general hospital and emergence of heterogeneous resistance to glycopeptide antibiotics among three isolates
20. Reduced susceptibility of staphylococcus to vancomycin: Japan 1996
21. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility
22. The emergence of Staphylococcus aureus with reduced susceptibility to vancomycin in Japan
23. Update: Staphylococcus aureaus with reduced susceptibility to vancomycin: United States, 1997
24. First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital
25. Staphylococcus aureus with reduced susceptibility to vancomycin isolated from a patient with fatal bacteremia
26. Vancomcycin resistant staphylococcus reported in Hung Kong
27. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides
28. Evaluation of bactericidal activities of LY333328, vancomycin, teicoplanin, ampicillin-sulbactam, trovafloxacin, and RP59500 alone or in combination with rifampin or gentamicin against different strains of vancomycin-intermediate Staphylococcus aureus by time-kill curve methods
29. In vitro activities of daptomycin, arbekacin, vancomycin, and gentamicin alone and/or in combination against glycopeptide-intermediate resistant Staphylococcus aureus in an infection model
30. Comparative in vitro activity of daptomycin versus vancomycin, linezolid, and synercid against methicillin-resistant and susceptible staphylococci, vancomycin-intermediate susceptible Staphylococcus aureus and vancomycin susce
31. Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains MU3 and MU50
32. Teicoplanin-resistant Staphylococcus aureus expresses a novel membrane protein and increases expression of penicillin-binding protein 2 complex
33. Overproduction of a 37-kilodalton cytoplasmic protein homologous to NAD+-linked D-lactate dehydrogenase associated with vancomycin resistance in Staphylococcus aureus
34. Characterization of Staphylococcus aureus isolates with decreased susceptibility to vancomycin and teicoplanin: Isolation and purification of a constitutively produced protein associated with decreased susceptibility
35. Analysis of vancomycin population susceptibility profiles, killing activity, and postantibiotic effect against vancomycin-intermediate Staphylococcus aureus
36. Reversion of glycopeptide intermediate-resistant Staphylococcus aureus associated with loss of type 5 capsule
37. Activity of vancomycin administered every 12 hours or as continuous infusion against two clinical strains of vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacodynamic model
38. Pharmacokinetic-pharmacodynamic indices for vancomycin treatment of susceptible and intermediate S. aureus in the neutropenic mouse thigh model
39. Activity of LY333328, an investigational glycopeptide, against three strains of vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacodynamic infection model
40. Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus
41. Suppression of beta-lactant antibiotic resistance in a methicillin-resistant Staphylococcus aureus through synergic action of early cell wall inhibitors and some other antibiotics
42. Pharmacodynamic predictors of activity for ampicillin/sulbactam and trovafloxacin versus vancomycin-intermediate Staphylococcus aureus in an in vitro infection model